Placebomics: Where placebo and genetics meet

December 01, 2017 – The placebome is a new game in town. That is where genetics and the placebo effect meet. The underlying discipline of study may well be “placebomics”, fitting genetics and the uniquely complex phenotype “Placebo Effect” into the -omics age of things. In fact, with the advent of genomics, researchers are learning that placebo responses are modified by a person’s genetics. In 2015, a review article explored the many questions that this raises regarding the role of the placebo in both patient care and in drug development.

Placebo has helped to ease symptoms of illness for centuries and have been a fundamental component of clinical research to test new drug therapies for more than 70 years. But why some people respond to placebos and others do not remains under debate. Genetic sequencing is revealing that the placebo response is, in fact, a complex phenotype with an unfolding physiology; the study of genomic effects on the placebo response, what some authors call “the placebome“, is in its infancy, but there is already ample evidence that genetic variations in the brain’s neurotransmitter pathways modify placebo effects. As a result, placebo responses are emerging as a legitimate series of molecular and biological reactions, most likely organized in complex (neurological) networks of interacting genes (and their respective coded for proteins) in the placebome (see the mind boggling 2017 article by Wang et al. in the Journal of Clinical Investigation for an overview).

The exciting question is now if there exist definitive genetic biomarlers which could be used to prospectively identify individuals who are perceptive for placebo responses? If so, how many of such genetic biomarkers exist? Can the medical field harness the placebo response to enhance personalized medical treatment? What might be the impact of placebo-drug interactions? And what will this new information mean for randomized clinical trials, which depend on

The placebome module.

placebo controls to test the efficacy of new drug candidates? Should a “no-treatment” control be added to future trials?

In 2012, a first genetic placebo biomarker, the catechol-O-methyltransferase (COMT) gene, was identified in that a genetic variation (in particular the exonic SNP (rs4680, Val158Met)) in COMT, which influences the brain’s levels of the neurotransmitter dopamine, also determined the extent of an individual’s placebo response in irritable bowl syndrome (IBS).

While traditionally scientists used behavioral instruments, such as personality measures, to predict which patients would respond to placebo, the development of sophisticated neuroimaging technologies over the last couple of years illuminated the activation of the brain’s neurotransmitter pathways in response to placebo. Because the regulation of these pathways (including dopamine, opioid, endocannabinoid and serotonin pathways) govern the chemical messengers (neurotransmitters) that either excite or inhibit nerve function in the brain, many neurotransmitters play key roles in reward and pain. It comes then as no surprise that genetic variation in the genes that encode the proteins in these neurotransmitter pathways might also modify placebo responses, the allelic variant Val158Met of COMT being a first example.

The article by Wang et al. (see above) further explores the concept of the placebome and puts it into relation to similar gene networks thought to be active in drug action (drug modules) and in disease aetiologies and responses to treatment (disease modules). Within this framework, the researchers hope to further decipher the physiological basis of placebo and to find the raisons for differences of the strength of placebo in diseases where this effect is high (such as  alcoholism, anxiety, asthma, Crohn’s disease, depression, diabetic neuropathies, duodenal ulcer, epilepsy, eating disorders, fibromyalgia, irritable bowel syndrome, Parkinson disease, migraine disorders, osteoarthritis, chronic pancreatitis, restless leg syndrome, schizophrenia, and ulcerative colitis) versus diseases where this effect is low or absent (such as bacterial infection, infertility, viremia, pneumothorax, uremia, hepatocellular carcinoma and renal cell carcinoma. There have been about 15 candidate genes identified which may be implicated at the origin of the placebo effect; further research will more clearly reveal their role, the involvement of particular mutations, and eventually allow to identify individuals, based on genetic tests, who are naturally carrying a strong placebo effect predispostion (giving rise to the field of placebomics).

Possibility of “Placebo-Drug Interactions” and “No-Treatment Arms” in Clinical Trials

Knowing that neurotransmitter pathways are involved in placebo responses now raises a new consideration for both patient care and clinical research. Since seemingly neurotransmitter pathways are modified by genetics and are pathways that both drugs and the placebo act on,  drugs could change a placebo response and a placebo response could modify a drug response. This potential overlap between placebo, drug treatment and disease adds to the complexity of the placebome and underscores the importance of understanding how it fits into larger more complex networks.

The possibility that there could be a placebo-drug interaction as a result of genetic variation in placebo pathway genes suggests that one needs to refine and recalibrate the assumptions of placebo controls in randomized clinical trials. An important next step in describing the placebome would be to include a no-treatment control in placebo-controlled randomized clinical trials. This approach might be cost effective and allow for a broad view of placebo response genes and other molecules across varying conditions and treatments.

It may no longer be sufficient for pharmaceutical research to include in randomized clinical trials a “placebo arm,” which is designed to control for the non-specific, non-pharmacological effects that are part of the administration and receipt of clinical treatment. In order to properly study the placebo response,  a frank “no -treatment” control may have to be incorporated into well designed future clinical trials. This may help to provide the right treatment in the right place at the right time, not only for the responding patient, but also for the “placebo patient”.

Note that Thasso Post had in the past articles on placebo entitled *Outssmarting the placebo effect” (here) and “Pain: Placebo’s sweet hot spot in the brain identified” (here).



Tags: , , , , , , , , , , ,
About the Author
Joseph Gut - thasso Ph.D.; Professor in Pharmacology and Toxicology. Senior expert in theragenomic and personalized medicine and individualized drug safety. Senior expert in pharmaco- and toxicogenetics. Senior expert in human safety of drugs, chemicals, environmental pollutants, and dietary ingredients.
1 Pings/Trackbacks for "Placebomics: Where placebo and genetics meet"

Your opinion


No comments yet

thasso: conditions

thasso: newest tweets

thasso: recent comments

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • Genetic discovery could lead to better prediction of suicide risk within families November 26, 2020
    Every 11 minutes, an American dies by suicide. That's 132 people a day or more than 48,000 annually. For those left behind, the haunting question is why.
  • The genetics of side-effects November 25, 2020
    Henk-Jan Guchelaar knows all too well the serious problems that the side-effects of medication can cause. As a professor of clinical pharmacy at the University of Leiden in the Netherlands, he has spent the last two decades trying to get the link between medicine and our genes recognised more widely.
  • Gene donors at high risk for cancer received feedback November 25, 2020
    Researchers at the Estonian Genome Center at the University of Tartu studied how people at high risk for breast, ovarian or prostate cancer responded to the feedback of genetic findings. Gene donors who chose to receive results appreciated being contacted and considered the information provided to be valuable. Authors find that knowing more about people's […]
  • Researchers reveal how genetic variations are linked to COVID-19 disease severity November 25, 2020
    Even as tens of thousands of Americans test positive for COVID-19 each day, physicians still aren't sure why some people experience mild to no symptoms while others become critically ill. New research led by Robert E. Gerszten, MD, Chief of the Division of Cardiovascular Medicine at Beth Israel Deaconess Medical Center (BIDMC) sheds new light […]
  • Study identifies new functions in the gene that causes Machado-Joseph disease November 25, 2020
    Ataxia is a minority disease with genetic origins, known for its neuromuscular alterations due to the selective loss of neurons in the cerebellum, the organ of our nervous systems which controls movement and balance. UB researchers have identified new functions in the ataxin 3 gene (ATXN3)–which causes Machado-Joseph disease, the most common type of ataxia– […]